Clinical Trials on Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Total 2277 results

Roswell Park Cancer Institute

Not yet recruiting

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditions

United States
John Lenehan

Not yet recruiting

CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) (CHASe-PDAC)

Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma

Canada
Georgetown University
ERYtech Pharma

Active, not recruiting

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; American Association for... and other collaborators

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
OHSU Knight Cancer Institute
Oregon Health and Science University

Not yet recruiting

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditions

United States
German Cancer Research Center
University Hospital Heidelberg

Recruiting

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify)

Pancreatic Cancer | Pancreatic Adenocarcinoma | CYP3A Inhibitor | Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm

Germany
University of Utah
National Cancer Institute (NCI)

Active, not recruiting

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...

United States
General Oncology, Inc.
Myriad Genetics, Inc.

Recruiting

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Instituto do Cancer do Estado de São Paulo

Completed

Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.

Pancreatic Adenocarcinoma Advanced or Metastatic

Brazil
GERCOR - Multidisciplinary Oncology Cooperative...
OSE Immunotherapeutics

Recruiting

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)

Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Locally Advanced Cancer

France
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; Servier Pharmaceuticals...

Recruiting

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8

United States
Fred Hutchinson Cancer Center
Lonza Walkersville, Inc.

Recruiting

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Stage IV Pancreatic Cancer AJCC v6 and v7 | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
MapKure, LLC

Recruiting

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Colorectal Cancer | Pancreatic Ductal Cancer | Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

United States
Memorial Sloan Kettering Cancer Center

Recruiting

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States, Israel, Canada
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Lexicon Pharmaceuticals

Active, not recruiting

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Recurrent Pancreatic Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Roswell Park Cancer Institute
Novartis

Completed

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Advanced Malignant Solid Neoplasm | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | ALK Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); AstraZeneca

Completed

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

United States
University Health Network, Toronto
Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Dana-Farber... and other collaborators

Active, not recruiting

Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Cancer

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
Panbela Therapeutics, Inc.

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV

United States, Belgium, Germany, Spain, Korea, Republic of, Australia, France, Italy, Austria, United Kingdom
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Vaccinex...

Completed

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditions

United States
Belgian Group of Digestive Oncology
University Hospital St Luc, Brussels

Recruiting

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) (NALPAC)

Metastatic Pancreatic Ductal Adenocarcinoma

Belgium
British Columbia Cancer Agency
Canadian Cancer Society (CCS); SignalChem Lifesciences Corporation

Terminated

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)

Metastatic Pancreatic Ductal Adenocarcinoma

Canada
University Hospital, Antwerp
Universitair Ziekenhuis Brussel; General Hospital Groeninge; AZ Nikolaas; Erasme... and other collaborators

Active, not recruiting

Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan (NALIRI)

Metastatic Pancreatic Ductal Adenocarcinoma

Belgium
Pfizer

Terminated

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Georgetown University
Merck Sharp & Dohme LLC; BioXcel Therapeutics Inc

Recruiting

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
National University Hospital, Singapore

Recruiting

A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Metastatic Pancreatic Ductal Adenocarcinoma

Singapore
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Metastatic Pancreatic Ductal Adenocarcinoma

United States, China, Hungary, Taiwan, Belgium, Germany, Spain, Italy, Czechia, France, Japan, Switzerland, Australia, Israel, Korea, Republic of, Canada, Russian Federation, Slovakia, United Kingdom, Turkey, Sweden, Greece, Finland, ... and more
M.D. Anderson Cancer Center

Active, not recruiting

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | KRAS NP_004976.2:p.G12D

United States
Sierra Oncology LLC - a GSK company

Terminated

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Pfizer
Celgene

Completed

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Metastatic Pancreatic Ductal Adenocarcinoma

United States, Spain

Clinical Trials on Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations